Study #2019-0384
A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of TPX-0022 in Adult Subjects with Locally Advanced or Metastatic NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations I
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-479-2433
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.